WCLC 2022 | CALGB 140503: sub-lobar resection non-inferior to lobectomy in stage IA node-negative NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, provides an overview of the Phase III CALGB140503 (Alliance) (NCT00499330) study investigating sub-lobar versus lobar resection in patients with non-small cell lung cancer (NSCLC). The primary endpoint was disease-free survival (DFS) and secondary endpoints included overall-survival (OS). The trial demonstrated sub-lobar resection is non-inferior to lobectomy in patients with NSCLC who have pathologically confirmed node-negative disease. DFS and OS were not deteriorated by a lesser surgical intention over lobectomy. This surgical approach spares lung capacity which allows a potentially multimodal approach for patients who require additional treatments in the future. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.